IVQ vs. PMN, PDP, WMD, APS, IOM, CRDL, MDNA, MBX, HEXO, and DOC
Should you be buying Invesque stock or one of its competitors? The main competitors of Invesque include ProMIS Neurosciences (PMN), Pediapharm (PDP), WeedMD (WMD), Aptose Biosciences (APS), Assure (IOM), Cardiol Therapeutics (CRDL), Medicenna Therapeutics (MDNA), Microbix Biosystems (MBX), HEXO (HEXO), and CloudMD Software & Services (DOC). These companies are all part of the "medical" sector.
Invesque vs.
ProMIS Neurosciences (TSE:PMN) and Invesque (TSE:IVQ) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, risk, profitability, valuation, community ranking and media sentiment.
2.2% of ProMIS Neurosciences shares are held by institutional investors. Comparatively, 27.1% of Invesque shares are held by institutional investors. 18.5% of ProMIS Neurosciences shares are held by company insiders. Comparatively, 31.0% of Invesque shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
ProMIS Neurosciences has a net margin of 0.00% compared to Invesque's net margin of -32.66%. Invesque's return on equity of -23.17% beat ProMIS Neurosciences' return on equity.
ProMIS Neurosciences received 180 more outperform votes than Invesque when rated by MarketBeat users. Likewise, 70.86% of users gave ProMIS Neurosciences an outperform vote while only 60.71% of users gave Invesque an outperform vote.
ProMIS Neurosciences has higher earnings, but lower revenue than Invesque. ProMIS Neurosciences is trading at a lower price-to-earnings ratio than Invesque, indicating that it is currently the more affordable of the two stocks.
In the previous week, Invesque had 3 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 3 mentions for Invesque and 0 mentions for ProMIS Neurosciences. ProMIS Neurosciences' average media sentiment score of 0.00 beat Invesque's score of -0.13 indicating that ProMIS Neurosciences is being referred to more favorably in the media.
ProMIS Neurosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Invesque has a beta of 0.98, meaning that its stock price is 2% less volatile than the S&P 500.
Summary
Invesque beats ProMIS Neurosciences on 8 of the 15 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IVQ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Invesque Competitors List
Related Companies and Tools